Neurotransmitter interactions in schizophrenia-therapeutic implications

European Archives of Psychiatry and Clinical Neuroscience

Volumn 249, Issue SUPPL. 4, 1999, Pages

  Carlsson, Arvid ^a   Waters, Nicholas ^a   Carlsson, Maria L ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Antipsychotics; Dopamine; Glutamate; Neurocircuits; Neurotransmitters; Schizophrenia

Indexed keywords

CLOZAPINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMIC ACID; NEUROLEPTIC AGENT; NEUROTRANSMITTER; SEROTONIN; SEROTONIN 2 ANTAGONIST;

ANIMAL MODEL; CONFERENCE PAPER; DOPAMINE RELEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SIDE EFFECT;

EID: 0343415639     PISSN: 09401334     EISSN: None     Source Type: Journal    
DOI: 10.1007/pl00014183     Document Type: Conference Paper

References (29)

1. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Laruelle M et al (1998) Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155:761-767
2. Ågren H, Reibring L. Hartvig P, Tedroff J, Bjurling P, Hornfeldt K et al (1991) Low brain uptake of L-[11C]5-hydroxytryptophan in major depression: a positron emission tomography study on patients and healthy volunteers. Acta Psychiatr Scand 83:449-455
3. Alexander GE, Crutcher (1990) Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends in Neurosci 13:266-271
4. Breier A, Su T-P, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A et al (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94:2569-2574
5. Carlsson A (1988) The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1:179-186
6. Carlsson A (1995a) The dopamine theory revisited. In: Hirsch SR and Weinberger DR (eds) Schizophrenia. Oxford: Blackwell Science, pp 379-400
7. Carlsson ML (1995b) The selective 5-HT2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse - implications for psychosis. J Neural Transm 100:225-237
8. Carlsson ML, Carlsson A (1989) The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm 75:221-226
9. Carlsson ML, Carlsson A (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends in Neurosci 13:272-276
10. Carlsson LM, Svensson A (1990) Interfering with glutamatergic neurotransmission by means of MK-801 administration discloses the locomotor stimulatory potential of other transmitter systems in rats and mice. Pharmacol Biochem Behav 36:45-50
11. Carlsson ML, Martin P, Nilsson M, Sorensen SM, Carlsson A, Waters S, Waters N (1999) The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist - than dopamine agonist-induced hyperactivity in mice. J Neural Transm 106:123-129
12. Dao-Costellana M-H, Paillère-Martinot M-L, Hantraye P, AttarLévy D, Rémy P, Crouzel C et al (1997) Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophrenia Research 23:167-174
13. Garland Bunney B, Bunney WE, Carlsson A (1995) Schizophrenia and glutamate. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, pp 1203-1214
14. Gellman RL, Aghajanian GK (1991) IPSPs in pyramidal cells in piriform cortex evoked by monoamine excitation of interneurons demonstrate a convergence of inputs. Society of Neuroscience Abstracts 17(1):989
15. 2 autoreceptor ligands. Modeling of dopamine synthesis and release in vivo by means of partial least squares regression. J Med Chem 38:3121-3131
16. Hietala J, Syvälahti E, Vuorio K, Någren K, Lehikoinen P, Ruotsalalainen U et al (1994) Striatal D2-dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch Gen Psychiatry 51: 116-123
17. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmüller (1980) Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 20:379-382
18. Lahti AC, Weiler MA, Corey PK, Lahti RA, Carlsson A, Tamminga CA (1998) Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in schizophrenia. Biol Psychiat 43:2-11
19. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E et al (1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 20, 93(17):9235-40
20. 11-labelled I-dopa and positron emission tomography (PET). Abstract, 36th Annual ACNP Meeting, December 8-12, 1997, p 290
21. Lodge D (1989) Modulation of N-methylaspartate receptor channel complexes. Drugs of Today 25:395-411
22. Martin P, Waters N, Schmidt CJ, Carlsson A, Carlsson ML (1998) Rodent data and general hypothesis: antipsychotic action exerted through 5-HT2A receptor antagonism is dependent on increased serotonergic tone. J Neural Transm 105:365-396
23. Miller DW, Abercrombie ED (1996) Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats. Brain Res Bull 40:57-62
24. Moghaddam B, Adams BW (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281:1349-1352
25. 2A receptors in antipsychotic activity. Life Sci 56:2209-2222
26. Sonesson C, Lin C-H, Hansson L, Waters N, Svensson K, Carlsson A et al (1994) Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: Synthesis and structure-activity relationships. J Med Chem 37: 2735-2753
27. Svensson K, Hjorth S, Clark D, Carlsson A, Wikström H, Andersson B et al (1986) (+)-UH 232 and (+)-UH 242: Novel stereo-selective DA receptor antagonists with preferential action on autoreceptors. J Neural Transm 65:1-27
28. Tamminga CA, Crayton JC, Chase TN (1978) Muscimol: GABA agonist therapy in schizophrenia. Amer J Psychiat 135:746-748
29. Waters N, Lundgren C, Hansson LO, Carlsson ML (1996) Concurrent locomotor stimulation and decrease in dopamine in rats and mice after treatment with the competitive NMDA receptor antagonists D-CPPene and CGS 19755. J Neural Transm 103: 117-129